The global DNA vaccine market was valued at US$ 553.89 million in 2024, grew to US$ 590 million in 2025, and is projected to reach US$ 1041.68 million by 2034, expanding at a CAGR of 6.52% (2025–2034). North America dominated in 2024, while Asia-Pacific is the fastest-growing region. Prophylactic vaccines held the largest market share, whereas therapeutic vaccines and cancer-based DNA therapies are the fastest-growing areas. Key players include Pfizer, AstraZeneca, BioNTech, Sanofi, Moderna, and Merck, supported by rising government investments and AI integration.
Download the free sample and get the complete insights and forecasts report on this market @ https://www.towardshealthcare.com/download-sample/5510
◉2023–2024 Size
2023: slightly below US$ 553 million (baseline year).
2024: US$ 553.89 million, driven by human and veterinary DNA vaccines.
◉2025 Value
Increased to US$ 590 million, supported by launches in oncology vaccines (Oncept) and animal vaccines (Apex-IHN).
◉Forecast by 2034
Market projected to reach US$ 1041.68 million, nearly doubling from 2025.
◉Growth Rate
CAGR of 6.52% (2025–2034), attributed to increased cancer immunotherapy demand, R&D focus, and AI-based vaccine design.
◉Regional Share 2024
North America: Largest contributor due to advanced healthcare and biotech hubs.
Asia-Pacific: Fastest CAGR, boosted by biotech expansion in India & China.
Europe: Significant growth driven by personalized medicine and gene therapy research.
◉March 2025: Oncovita, Institut Pasteur & Unither formed a partnership to manufacture a new prophylactic vaccine for children, highlighting multi-player collaborations.
◉March 2025: PGV001 neoantigen vaccine developed at Icahn School of Medicine (Mount Sinai). Enables immune system to recognize and kill cancer cells, tested successfully in small patient groups.
◉AI tools (e.g., epitope prediction, antigen optimization, adjuvant discovery) revolutionize cancer and infectious disease vaccine development.
◉Oncept (canine melanoma) and Apex-IHN (aquaculture infections) drive veterinary sector growth.
◉China, 2025: Testing of engineered herpes simplex virus therapy for advanced cancer patients.
◉Growing tie-ups between universities, biotech startups, and pharma giants accelerate innovation.
◉AI predicts immunogenic epitopes that stimulate stronger immune responses.
◉Machine learning models rank potential antigens for infectious disease & cancer vaccines.
◉AI screens novel adjuvants that boost DNA vaccine response, reducing trial-and-error R&D.
◉AI tailors DNA vaccines for individual tumor mutations, enhancing neoantigen discovery.
◉Example: VERDI Solutions (Austria) develops AI + cloud-based personalized cancer vaccine platforms.
◉Algorithms forecast vaccine safety, stability, and immune response, optimizing trial success.
◉Integration of genomic datasets + AI improves vaccine-target matching, particularly in oncology and autoimmune disorders.
◉March 2025: DYNA AI Tool by Cedars-Sinai links gene mutations to diseases, enhancing precision medicine applications for DNA vaccines.
United States:
◉Largest contributor due to NIH, BARDA, and FDA-driven funding pipelines.
◉Strong regulatory pathways for DNA vaccine trials → rapid emergency approvals during outbreaks (Ebola, COVID-19 legacy).
◉Presence of top biotech clusters (Boston, San Francisco) with integration of AI-driven R&D.
Canada:
◉Known for academic-industry collaborations (University of Toronto, McGill with biotech startups).
◉Government funds vaccine hubs under Strategic Innovation Fund.
◉Growing veterinary vaccine research for livestock and aquaculture.
China:
◉Heavy government-backed biotech investment under Made in China 2025.
◉Large clinical trial network with emphasis on DNA vaccines for infectious diseases and cancer immunotherapy.
◉Domestic players (e.g., CanSino Biologics) are entering DNA vaccine development.
India:
◉Holds world’s largest vaccine manufacturing capacity (e.g., Serum Institute of India, Bharat Biotech).
◉Government supports low-cost, mass distribution DNA vaccines for tuberculosis and vector-borne diseases.
◉Investments in gene therapy facilities (Hyderabad emerging as biotech hub).
Japan & South Korea:
◉Japan: Focus on personalized medicine, oncology DNA vaccines, and collaborations with U.S. biotech firms.
◉South Korea: Investments in cell and gene therapy hubs; Samsung Biologics expanding DNA vaccine CDMO services.
Germany:
◉Strong biotech-pharma partnerships (BioNTech, CureVac).
◉Emphasis on large-scale vaccine production and automation.
United Kingdom:
◉Strong clinical trials ecosystem.
◉Post-COVID momentum: Oxford and Imperial College leading DNA vaccine innovation.
France & Nordics:
◉France investing in next-gen DNA vaccines for oncology and rare diseases.
◉Nordic countries (Sweden, Denmark) focusing on AI-driven vaccine development and biotech startups.
Brazil:
◉Rising demand for DNA vaccines against Zika, TB, chikungunya.
◉Government partnering with foreign firms for local production facilities.
Mexico:
◉Early-stage clinical trials for DNA vaccines against vector-borne diseases.
◉Cross-border collaborations with U.S. and European biotech companies.
◉Rising government-backed immunization campaigns against malaria, dengue, and TB.
◉South Africa: Investment in domestic biotech hubs for vaccine research.
◉UAE: Dubai Science Park investing in local biomanufacturing and personalized DNA therapies.
Infectious Disease Burden (Vector-borne & zoonotic)
◉Mechanism: DNA platforms enable rapid antigen swapping and multivalent constructs for dengue/Zika/malaria/TB, shortening design-to-IND cycles versus traditional methods.
◉Where demand concentrates: Tropical belts in LATAM, Sub-Saharan Africa, South & Southeast Asia; spillover to travelers’ vaccines in North America/Europe.
◉Operational enablers: Outbreak surveillance data, ring-vaccination logistics, and stockpile frameworks (national & multilateral).
◉What to watch: Seasonality spikes (rainy season for vectors), urbanization near vector habitats, climate-linked shifts in mosquito range, and government procurement tenders.
Cancer Prevalence & Immuno-Oncology Adoption
◉Mechanism: Patient-specific neoantigen DNA vaccines prime T-cell responses and pair with checkpoint inhibitors to convert “cold” tumors to “hot.”
◉High-yield niches: Melanoma, HPV-related cancers, certain GI tumors; veterinary oncology (e.g., canine melanoma) as proof-of-concept and revenue bridge.
◉Clinical & commercial levers: Biomarker-driven patient selection, adaptive trial designs, and hospital-based small-batch GMP units for faster turnaround.
◉What to watch: Objective response rates with combo regimens, durability of response, and real-world evidence informing reimbursement.
Personalized Medicine Momentum
◉Mechanism: Tumor exome → AI/ML epitope ranking → plasmid design → small-batch GMP. Turnaround time drives clinical utility.
◉Economic logic: Smaller volumes but higher value per patient; premium pricing offset by potential reduction in relapse and hospitalization costs.
◉Enablers: Hospital-adjacent modular manufacturing, integrated diagnostics, cloud pipelines for sequence-to-vaccine design.
◉What to watch: Turnaround time (days–weeks), percentage of supercoiled plasmid purity, and release-testing automation (RTRT).
Veterinary Applications (Livestock & Aquaculture)
◉Mechanism: DNA vaccines reduce mortality in high-density systems (salmon/shrimp farms; poultry/swine) where outbreaks are economically catastrophic.
◉Adoption drivers: Lower regulatory hurdles vs human, measurable ROI for producers, and simpler cold-chain relative to many biologics.
◉What to watch: Expansion of aquaculture outputs, emergence of new farm pathogens, and insurance/retailer demands for vaccination standards.
Cold-Chain Stability & Field Logistics
◉Root cause: Plasmid integrity (supercoiled fraction) and certain delivery systems degrade with heat/light/humidity.
◉Impact: Potency loss, batch wastage, higher COGS in Africa/South Asia last-mile settings.
◉Mitigations: Lyophilized formats, stabilizing excipients, solar-powered fridges, validated passive shippers, and temperature-excursion IoT monitors.
◉Residual risk: Human error in peripheral clinics, prolonged customs delays, and fragmented rural distribution networks.
Delivery Modality Challenges
◉Root cause: LNP/polymeric carriers can aggregate; electroporation adds hardware cost, training, and clinic time.
◉Impact: Variable transfection → inconsistent immunogenicity; potential for local reactogenicity impacting patient acceptance.
◉Mitigations: Ionizable-lipid libraries with tighter PDI control, shear-minimizing mixing, device miniaturization, single-use electrodes, and nurse-friendly workflows.
◉Residual risk: Scale-up reproducibility and multi-site device standardization.
Manufacturing & Quality Bottlenecks (cross-cutting)
◉Root cause: Limited global capacity for high-purity plasmid DNA, skilled QC staff, and high-grade raw materials (resins/enzymes).
◉Impact: Longer lead times, price volatility, and tech-transfer drag for new plants.
◉Mitigations: Dual-sourcing, platformized purification (membrane chromatography, TFF), digital batch records, and vendor-managed inventory.
Regulatory & Reimbursement Uncertainty (therapeutic vaccines)
◉Root cause: Heterogeneity in endpoints (DFS vs OS), companion diagnostics, and combination therapy pricing.
◉Impact: Slower HTA decisions and fragmented market access.
◉Mitigations: Early payer engagement, pragmatic trials capturing QoL/utilization, and outcomes-based contracts.
Next-Gen Cancer Therapies & Combinations
◉Playbook: Pair DNA vaccines with PD-1/PD-L1, CTLA-4, or oncolytic vectors; sequence with radiation/chemo to enhance antigen release.
◉Value unlock: Higher response and durability can justify premium pricing; pathway exclusivity via IP on neoantigen selection + delivery device integration.
◉Execution needs: Rapid sequencing pipelines, GMP micro-factories, and standardized combo protocols across centers.
AI-Driven Vaccine Design & Smart Manufacturing
◉Scope: Antigen/epitope ranking, adjuvant discovery, manufacturability scoring (codon usage, GC content), and digital twins for bioreactor control.
◉KPIs: Design-to-GMP lead time, prediction accuracy vs immunogenicity readouts, batch-release cycle time.
◉Upside: Fewer failed constructs, tighter COGS, and faster iteration for outbreak variants.
Global R&D & Procurement Investments
◉Mechanisms: Government grants for early trials, public stockpiles for vector-borne threats, and PPPs for regional plants in India/China/APAC.
◉Commercial angle: Volume visibility via tenders; risk-sharing lowers WACC for capacity build-outs.
◉Where to focus: Countries expanding immunization schedules and aquaculture/livestock biosecurity mandates.
◉Veterinary & One-Health Convergence
◉Rationale: Shared pathogens and surveillance; cross-sector data improves early warning and target selection.
◉Monetization: Portfolio strategies that bundle human & animal vaccines for governments and agribusinesses.
◉Modular, single-use GMP suites near major hospitals for personalized oncology vaccines (cycle times trending to 2–3 weeks).
◉Real-Time Release Testing (RTRT) and inline analytics to cut QC bottlenecks.
◉Lyophilized and temperature-tolerant presentations for last-mile markets.
◉Device simplification (portable electroporation, pre-filled kits) to enable decentralized administration.
◉Upstream: Demand for high-copy plasmid backbones, GMP-grade enzymes/resins; supplier consolidation raises bargaining power.
◉Midstream (Manufacturing): Continuous/semicontinuous plasmid processes + membrane chromatography reduce COGS; AI scheduling increases asset utilization.
◉Downstream (Distribution): Cold-chain validation, serialized tracking, and device availability (if required) define service levels.
◉Providers/Payers: Hospitals adopt if workflow is predictable; payers seek clear surrogate endpoints and budget impact models for therapeutic vaccines.
◉Cold-chain improvement: Each 10% reduction in temperature excursions can materially lower wastage and improve effective supply in hot climates.
◉Manufacturing yield: +5–10% plasmid yield via process optimization meaningfully reduces $/dose for prophylactic programs.
◉Turnaround time (personalized): Cutting design→dose from 6–8 weeks to ≤3 weeks improves clinical adoption and patient eligibility windows.
◉Combo therapy efficacy: Even modest ORR gains (e.g., +5–8 pp) with DNA+checkpoint can change HTA decisions in select tumors.
◉Biological: Tumor heterogeneity and immune escape may cap therapeutic benefit in some indications.
◉Operational: Device supply or consumable shortages delaying rollouts.
◉Policy: Shifts in donor or government budgets affecting procurement cycles; evolving GMO/nucleic-acid regulations.
◉Market: Competition from mRNA, viral vectors, and protein subunits in both prophylactic and oncology settings.
◉Strength: Extensive oncology + infectious disease DNA vaccine pipeline.
◉Global footprint with established manufacturing and distribution networks.
◉Partnerships: Multiple biotech collaborations for oncology DNA vaccines.
◉Known for its mRNA-COVID success, now pivoting into DNA-based oncology vaccines.
◉Heavy AI-driven R&D pipeline.
◉Collaborations with European research institutes and large pharma.
◉Expanding into DNA vaccines alongside its traditional vaccine dominance.
◉Achieved 10.3% YoY growth in vaccines (2025).
◉Leveraging large-scale vaccine production in Europe.
◉Transitioning from mRNA vaccines to DNA-based cancer immunotherapies.
◉Focused on rare diseases and personalized oncology.
◉Active partnerships with academic medical centers in the U.S.
◉Leader in therapeutic cancer vaccines.
◉Known for Keytruda synergies with DNA vaccine candidates.
◉Strategic focus on immuno-oncology markets.
◉Diversified portfolio including gene therapy + DNA vaccines.
◉Oncology-focused programs.
◉Collaborating with UK and EU academic institutions.
◉Specializes in cell & DNA-based immunotherapies.
◉Legacy of Provenge cancer immunotherapy, now advancing DNA cancer vaccine trials.
◉Strong oncology DNA vaccine pipelines.
◉Active in Japan and global partnerships for next-gen personalized therapies.
◉Specialized expertise in HIV and Zika DNA vaccines.
◉Multiple clinical trials ongoing in infectious disease prevention.
◉Leader in vector-based and DNA vaccines.
◉Active in infectious diseases (monkeypox, Ebola, HIV).
◉Partnerships with U.S. defense agencies for DNA vaccine trials.
Pipeline Expansion
◉Big pharma is acquiring biotech firms with specialized DNA vaccine candidates (infectious disease + oncology).
Manufacturing Scale-Up
◉Acquisitions target plasmid DNA production companies and biomanufacturing CDMOs to secure supply chains.
Technology Access
◉Deals often focus on delivery platforms (LNPs, electroporation devices, viral vectors) to overcome DNA vaccine delivery hurdles.
Geographic Expansion
◉M&A allows entry into high-growth markets like Asia-Pacific and Latin America, where DNA vaccines are gaining adoption.
◉Acquisition Strategy: Focus on next-gen vaccines beyond mRNA.
◉Key Activity: Expanded partnerships with DNA vaccine innovators in oncology and infectious diseases.
◉Impact: Strengthened position in DNA + mRNA hybrid vaccine approaches.
◉M&A Direction: Moving beyond mRNA into DNA vaccine oncology programs.
◉Recent Moves: Acquired small biotech startups specializing in plasmid optimization and AI-based vaccine design tools.
◉Strategic Goal: Build a dual nucleic acid portfolio for cancer and infectious diseases.
◉Partnership & Acquisitions: Targeted acquisitions in AI-driven personalized vaccine platforms.
◉Notable Acquisition: European bioinformatics startup to enhance its personalized DNA oncology vaccine R&D pipeline.
◉Impact: Accelerated entry into individualized cancer vaccines.
◉Expansion Strategy: Strengthened through acquisition of DNA vaccine biotechs in the U.S. and EU.
◉Recent Activity: Invested in firms working on veterinary DNA vaccines and vector-borne diseases.
◉Strategic Goal: Broaden footprint in human + veterinary vaccine portfolio.
◉Therapeutic Cancer Focus: M&A aimed at acquiring companies with DNA-based immuno-oncology vaccines.
◉Key Partnership: Entered licensing deals with biotech firms specializing in neoantigen DNA vaccines.
◉Acquisition Play: Acquired stakes in gene therapy startups that overlap with DNA vaccine tech.
◉Focus Area: Expanding in oncology and rare diseases via DNA-based therapeutics.
Collaborative M&A & Licensing:
◉Geovax: Licensing deals in HIV and Zika DNA vaccine programs.
◉Bavarian Nordic: Partnered/acquired companies with vector-based vaccine IP.
◉Dendreon: Expanded into DNA-based cell therapy collaborations.
◉Astellas: Strategic acquisitions for oncology-targeted DNA vaccine trials in Asia.
Electroporation Devices
◉Pharma acquiring medical device firms that specialize in in vivo electroporation systems, critical for DNA vaccine delivery.
Nanoparticle Startups
◉Multiple acquisitions of LNP and polymeric nanoparticle companies to overcome DNA delivery and stability issues.
AI & Genomic Data Firms
◉Big pharma acquiring AI-powered bioinformatics platforms (like VERDI in Vienna) for rapid vaccine personalization.
North America
◉Highest deal activity, driven by U.S.-based biotech startups and NIH-funded spinouts.
Europe
◉Focused on acquisitions of AI-driven oncology vaccine firms and gene therapy startups.
Asia-Pacific
◉China and India seeing strategic joint ventures instead of outright acquisitions, especially in vaccine manufacturing hubs.
Latin America & MEA
◉Still in early stages, mostly licensing agreements and regional manufacturing partnerships.
Accelerated Innovation: Large pharma gains immediate access to advanced DNA vaccine technologies.
Supply Chain Security: Consolidation ensures plasmid DNA and delivery system availability.
Competitive Advantage: Companies secure exclusive IP rights for DNA oncology and infectious disease vaccines.
Market Growth: Strengthened regional presence, especially in Asia-Pacific and emerging markets.
High-Yield Fermentation
◉Traditional E. coli fermentation platforms are being replaced with high-density fed-batch fermentation, which increases plasmid yield while lowering impurities.
◉Use of novel bacterial strains with optimized promoters ensures higher copy numbers of plasmids with consistent purity.
Endotoxin-Free Strains
◉Manufacturers now employ endotoxin-free E. coli strains to minimize downstream purification needs, reducing production cost and time.
Continuous Bioprocessing
◉Adoption of perfusion bioreactors allows continuous harvest of plasmid DNA, reducing batch failures and increasing manufacturing flexibility.
Chromatography Enhancements
◉Membrane chromatography (anion-exchange and hydrophobic interaction) replacing resin-based systems → increases throughput.
◉Enables scalable purification with reduced buffer use, aligning with sustainable manufacturing goals.
Tangential Flow Filtration (TFF)
◉Advanced TFF systems now provide high plasmid recovery and faster purification cycles.
◉Allows manufacturing facilities to maintain quality while meeting regulatory requirements for large-scale clinical trials.
Lipid Nanoparticles (LNPs)
◉Modified from mRNA vaccine tech, LNPs now being optimized for DNA delivery.
◉Advances in ionizable lipids enhance DNA stability and cellular uptake, reducing required doses.
Polymeric Nanoparticles
◉Use of biodegradable polymers (PLGA, chitosan) in encapsulation → sustained release and enhanced transfection efficiency.
Electroporation Devices
◉Next-gen electroporation systems (portable, automated) are being integrated into point-of-care vaccination, improving DNA uptake in human and veterinary use.
AI for Plasmid Design & Optimization
◉AI tools (e.g., DYNA by Cedars-Sinai, VERDI’s AI-cloud) predict gene expression levels and optimize plasmid sequences for manufacturability.
Digital Twins in Manufacturing
◉Virtual models of bioreactors and purification lines simulate and predict plasmid yields, reducing errors before scaling up.
Robotic Automation
◉Fully automated plasmid DNA assembly lines reduce contamination risk and improve reproducibility.
On-Demand Vaccine Manufacturing Units
◉Modular facilities equipped with single-use bioreactors enable localized, rapid production for outbreak regions.
◉These small-footprint plants can be deployed in low-resource settings (Africa, Southeast Asia) to meet outbreak-specific demands.
Personalized Cancer Vaccines
◉Small-batch GMP facilities now designed for patient-specific oncology vaccines, with batch timelines reduced from months to 2–3 weeks.
High-Resolution Analytical Techniques
◉Capillary electrophoresis, nanopore sequencing, and qPCR used to ensure plasmid integrity and supercoiled DNA percentage.
Real-Time Release Testing (RTRT)
◉Inline sensors monitor plasmid quality in real time, cutting down traditional quality control delays.
Regulatory Alignment
◉FDA and EMA are pushing quality-by-design (QbD) frameworks → forcing companies to integrate advanced analytics into manufacturing pipelines.
Single-Use Systems (SUS)
◉Disposable bioreactors and tubing lower cleaning costs, reduce cross-contamination, and increase batch flexibility.
Continuous Manufacturing Models
◉Moving away from batch-based plasmid production to continuous plasmid manufacturing, reducing costs by 30–40%.
Energy-Efficient Bioreactors
◉New low-energy cooling and aeration systems support sustainability goals, making DNA vaccine manufacturing eco-friendly.
Low-Cost Plasmid Platforms
◉Simplified plasmid production pipelines designed for mass veterinary immunization (livestock, aquaculture).
Oral DNA Vaccine Formats
◉Fish vaccines being developed as oral capsules coated with biopolymers, reducing injection-based administration costs.
◉March 2025: Bharat Biotech launched cell & gene therapy facility in Hyderabad → strengthens DNA vaccine oncology programs.
◉March 2025: Yale University created T-cell stimulating anti-cancer DNA vaccine focusing on long-term immunity.
◉March 2025: Cedars-Sinai developed DYNA AI tool mapping gene mutations → enabling patient-personalized DNA vaccines.
◉March 2025: VERDI Solutions (Vienna) launched AI-cloud cancer vaccine platform → accelerating clinical trial readiness.
◉Oncept: Market leader, canine melanoma DNA vaccine.
◉West Nile-Innovator: Widely used in veterinary immunization.
◉Apex-IHN: Emerging fastest in aquaculture sector.
◉Prophylactic: Dominant for infectious disease prevention.
◉Therapeutic: Fastest growth segment in cancer immunotherapy.
◉Vector-borne Diseases: Largest share (malaria, dengue, Zika).
◉Cancer: Fastest-growing (immuno-oncology & personalized therapies).
◉Human DNA Vaccines: Largest contributor.
◉Animal DNA Vaccines: Growing in veterinary & aquaculture.
◉Hospitals: Largest consumer base.
◉Research Institutes: Fastest growth (academic-industry partnerships).
◉North America: Largest market.
◉Asia-Pacific: Fastest growth rate.
◉Europe, Latin America, MEA: Emerging contributors with unique local drivers.
Q1. What is the size of the DNA vaccine market in 2025?
A1. The market is valued at US$ 590 million in 2025, projected to reach US$ 1041.68 million by 2034.
Q2. Which region dominates the DNA vaccine market?
A2. North America dominated in 2024, while Asia-Pacific will grow fastest by 2034.
Q3. Which vaccine type leads the market?
A3. Prophylactic vaccines dominate, while therapeutic vaccines show the fastest growth.
Q4. Which company reported the highest vaccine sales growth in 2025?
A4. Sanofi reported 10.3% YoY vaccine sales growth, driven by Beyfortus & flu vaccines.
Q5. What role does AI play in DNA vaccine development?
A5. AI accelerates antigen discovery, adjuvant selection, epitope prediction, and personalized cancer vaccine design.
Access our exclusive, data-rich dashboard dedicated to the healthcare market – built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.
Access the Dashboard: https://www.towardshealthcare.com/access-dashboard
Immediate Delivery Available | Buy This Premium Research @ https://www.towardshealthcare.com/price/5510
Become a valued research partner with us – https://www.towardshealthcare.com/schedule-meeting
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
Europe Region – +44 778 256 0738
North America Region – +1 8044 4193 44
Web: https://www.towardshealthcare.com
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | Pinterest
The global nootropics market size reached USD 5.71 billion in 2025 and is projected to grow to USD 19.53 billion… Read More
The U.S. concierge medicine market was valued at USD 7.25 billion in 2024, grew to USD 8 billion in 2025,… Read More
The global recombinant proteins market is valued at USD 3.36 billion in 2025 and projected to reach USD 8.08 billion… Read More
The global digital biomarkers market was valued at USD 5.09 billion in 2025 and is projected to reach USD 32.37… Read More
The global chemotherapy market is estimated at USD 10.28 billion in 2025 and projected to reach USD 19.35 billion by… Read More
The global endoscopy devices market was valued at USD 61.1 billion in 2024, increased to USD 63.44 billion in 2025,… Read More